CSL

CSL is a global biopharma leader that develops and delivers lifesaving medicines for haemophilia, immune deficiencies, and a range of plasma‑derived therapies, as well as influenza vaccines and treatments for iron deficiency, dialysis, and nephrology. The company’s portfolio is supported by three operating units—CSL Behring, CSL Seqirus, and CSL Vifor—serving patients in more than 100 countries. With a workforce of over 29,000, CSL combines deep scientific expertise, a robust R&D pipeline, and operational excellence to bring innovative therapies to market efficiently. Its long‑standing commitment to life‑saving science, rooted in a 1916 founding, distinguishes CSL as a trusted partner for patients and healthcare providers worldwide.